Biotech entity

Broadcom

Company AVGO

gene-therapy is the sole category represented across all 1 tracked stories. Broadcom is most often covered alongside KRESLADI, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline.

Last mentioned: 6d ago

Entity pulse

Recent coverage · Broadcom

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Broadcom

gene-therapy is the sole category represented across all 1 tracked stories. Broadcom is most often covered alongside KRESLADI, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 6 in the same window. Broadcom appears in 1 tracked Biotech story from March 19, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Broadcom. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Stock Volatility

    RCKT shares decline 4.4% amid sector-wide growth stock pressure and regulatory uncertainty.

  2. SEC Filing 8-K

    Company enters into a new material definitive agreement and terminates a previous facility.

  3. FY 2025 Earnings

    Rocket Pharmaceuticals reports full-year 2025 results and provides pipeline updates.

Stories mentioning Broadcom 1

Gene & Cell Therapy Neutral

Rocket Pharmaceuticals Shares Slide 4.4% Amid Regulatory and Financing Shifts

Rocket Pharmaceuticals (RCKT) shares declined 4.4% on March 19, 2026, as investors weighed a recent shift in the company's financial agreements against ongoing regulatory timelines for its lead gene therapy programs. The drop outpaced broader market movements, reflecting specific volatility in the rare disease gene therapy sector.

2 sources

Source: themarketsdaily.com · dailypolitical.com

Broadcom is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.